Allogene Therapeutics SEC filings document the regulatory record of a clinical-stage biotechnology company developing allogeneic CAR T product candidates. The filings cover material-event reports, operating and financial updates, common stock registration and offering activity, and clinical disclosures involving programs such as cema-cel in large B-cell lymphoma and ALLO-329 in autoimmune disease.
Allogene's proxy materials describe annual meeting proposals, shareholder voting matters, board governance, executive compensation, and equity award disclosures. Other filings address Nasdaq-listed common stock, capital-structure changes, material agreements, and risk factors tied to research and development, clinical execution, regulatory matters, intellectual property, and licensed gene-editing technology used in its allogeneic CAR T programs.
BlackRock, Inc. reported beneficial ownership of 23,211,736 shares of Allogene Therapeutics, Inc. (ALLO) common stock, or 6.7% of the class, as of September 30, 2026. It reported sole voting power over 22,733,488 shares and sole dispositive power over 23,211,736 shares, with no shared voting or dispositive power.
The reported position covers certain BlackRock business units and excludes securities attributed to units whose ownership is disaggregated. Various persons may receive dividends or sale proceeds, but no one person's interest in Allogene common stock exceeds 5% of the total outstanding shares.
Allogene Therapeutics, Inc. Chief Financial Officer Geoffrey M. Parker sold 36,342 common shares on October 21, 2026, at $1.34 per share. The sale covered tax withholding obligations tied to vesting restricted stock units and was required under the issuer’s equity incentive plan, not a discretionary trade. Reported holdings after the transaction were 1,045,877 shares; that figure reflects forfeiture of 195,000 performance RSU shares and includes 12,500 shares acquired March 15, 2026, and 11,924 acquired September 15, 2026, through the employee stock purchase program. No Rule 10b5-1 plan is reported.
Allogene Therapeutics, Inc. officer Geoffrey M. Parker reported a proposed sale of 36,342 common shares, with an approximate sale date of October 21, 2026, through Morgan Stanley Smith Barney LLC on Nasdaq. The notice lists an aggregate market value of $48,698.28. It also reports that 100,000 common shares were acquired on October 20, 2026, through vesting of a restricted stock unit award under the issuer’s equity compensation plan.
Allogene Therapeutics, Inc. (ALLO) reports that the TPG Funds—TPG Carthage Holdings, L.P. and The Rise Fund Carthage, L.P.—sold an aggregate of 18,716,306 shares of common stock on September 28, 2026, at $1.55 per share. After the sale, reporting persons TPG GP A, LLC, James G. Coulter, TPG Inc.'s Executive Chairman, and Jon Winkelried, its Chief Executive Officer, stated they no longer beneficially owned any shares. They also ceased to be beneficial owners of more than 5% of the class on September 28, 2026.
Allogene Therapeutics, Inc. (ALLO) announced that Geoffrey Parker, its Executive Vice President, Chief Financial Officer and principal financial officer, has notified the company of his retirement from all positions. His retirement will be effective November 6, 2026, following notice given on August 31, 2026. The report is signed by President and Chief Executive Officer Zachary Roberts, M.D., Ph.D.
Allogene Therapeutics, Inc. (ALLO) reported that officer Douglas Earl Martin, SVP and General Counsel, sold 29,697 shares of common stock on August 21, 2026 at $2.12 per share. The shares were sold to cover tax withholding on vesting RSUs under a mandated "sell to cover" arrangement, so the trade was not discretionary. After this and related adjustments, including forfeiture of performance RSUs and prior ESPP purchases, he directly holds 488,267 shares of Allogene common stock.
Allogene Therapeutics, Inc. (ALLO) is the issuer of common stock for which Douglas Earl Martin, an officer, has filed a notice under Rule 144 to sell up to 29,697 shares of common stock through Morgan Stanley Smith Barney LLC on or after 08/21/2026, with an aggregate market value of $62,957.64. The shares relate to a restricted stock unit award, with 81,719 shares vesting on 08/20/2026 as part of the issuer's equity compensation plan.
Allogene Therapeutics, Inc. received an amended Schedule 13G filing reporting the beneficial ownership of its Common Stock by multiple Frazier Life Sciences investment entities and two individuals. The filing states that Frazier Life Sciences Public Fund, L.P. directly holds 19,445,046 shares of Common Stock, representing 5.6% of the class, based on 345,154,561 shares outstanding as of May 11, 2026.
Additional Frazier Life Sciences funds directly hold 306,906, 753,251, and 1,941,465 shares, with related ownership percentages of 0.1%, 0.2%, and 0.6%, respectively. James N. Topper and Patrick J. Heron share voting and investment power over the 306,906 shares held by Frazier Life Sciences X, L.P., while the filing includes customary disclaimers that it does not constitute an admission of beneficial ownership beyond what is specifically described.
Allogene Therapeutics, Inc. filed a Form S-3 shelf registration allowing it to offer and sell, from time to time after effectiveness, up to $500,000,000 of common stock, preferred stock, debt securities and warrants, including securities issuable upon conversion or exercise. This is a primary shelf for future capital-raising transactions, with specific terms (security type, amount, pricing and ranking) to be detailed in accompanying prospectus supplements for each takedown.
Allogene is a clinical-stage immuno-oncology company developing genetically engineered allogeneic “off‑the‑shelf” T cell product candidates for cancer and autoimmune diseases. Net proceeds from any offerings are intended for general corporate purposes, including clinical trials, research and development, general and administrative expenses, capital expenditures, and potentially in‑licensing or acquiring complementary businesses, assets or technologies. Allogene’s common stock trades on the Nasdaq Global Select Market under the symbol ALLO, and the last reported sale price was $2.12 per share on August 11, 2026.